

Supporting information:

Substituted 4,5'-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase II α

Kaja Bergant Loboda^{1,3}, Matej Janežič², Martina Štampar⁴, Bojana Žegura⁴, Metka Filipič⁴ and
Andrej Perdih^{1*}

¹National Institute of Chemistry, Hajdrihova 19, SI 1000 Ljubljana, Slovenia

*²Structural Bioinformatics Team, Division of Structural and Synthetic Biology, Center for Life
Science Technologies, RIKEN, 1-7-22 Suehiro, Tsurumi, Yokohama, Kanagawa, 230-0045,
Japan*

³University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7 SI 1000 Ljubljana, Slovenia

*⁴National Institute of Biology, Department of Genetic Toxicology and Cancer Biology, Večna
pot 111, 1000 Ljubljana, Slovenia*

** Corresponding author:*

Andrej Perdih

National Institute of Chemistry

Hajdrihova 19, SI-1001 Ljubljana, Slovenia

Tel.: +386-1-4760-376

e-mail: andrej.perdih@ki.si

1. Tested commercially available substituted 4,5'-bithiazoles

Table S1. List of compounds tested for their inhibitory activity on human topo II α

Number	Chemical code	Vendor
1	STK163157	VitasM Labs ¹
2	7872757	ChemBridge ²
3	7858097	ChemBridge ²
4	7211760312	Otava ³
5	STK015148	VitasM Labs ¹
6	7859208	ChemBridge ²
7	5936031	ChemBridge ²
8	5934630	ChemBridge ²
9	5935030	ChemBridge ²
10	5932095	ChemBridge ²
11	STK070262	VitasM Labs ¹
12	5932282	ChemBridge ²
13	5935989	ChemBridge ²
14	7211760371	Otava ³

2. Validation of the docking procedure and molecular docking of substituted 4,5'-bithiazoles





Figure S1. Comparison of the docked and x-ray conformation of AMP-PNP in the ATP human topo II α binding site using GoldScore scoring function (PDB: 1ZXN). RMSD of 0.9 Å between heavy atoms of both poses was obtained.

Table S2. (above) 2D Intermolecular interaction pattern of the AMP-PNP ligand in the ATP bindings sites of both type II topoisomerases. (bellow) Selected amino acid pairs, important for ATP binding, that are equal/similar or different in the ATP binding sites of human topo II α and DNA gyrase.



*residue pair Pro126(htII α)/Arg136(DNA Gyrase) is listed since ARG136 plays a role in binding of 4,5'-bithiazole compound **13** to the DNA Gyrase ATP binding site.




Figure S2. Docking binding mode of compound **13** in the DNA gyrase ATP binding site generated using gyrase crystal structure with the bound AMP-PNP substrate (PDB: 1E11).




Figure S3. Proposed docking binding modes of active substituted 4,5'-bithiazole **9** in the human topo II α ATP binding site (PDB: 1ZXN).

3. Comparison of the bacterial DNA gyrase vs. human topoisomerase II α inhibition activities for compounds selected by both virtual screenings

Table S3. Comparison of the human topo II α and bacterial DNA Gyrase inhibition vales for compounds that were selected in this screening assays as well as also by our previous virtual screening campaign on bacterial DNA Gyrase [ref 39].

Compound	IC₅₀ [μM] bacterial DNA gyrase	IC₅₀ [μM] human topo IIα
5	8.2	70.1
6	67	37.7
8	5.5	119.7
12	30.0	192.9
13	1.1	123.0

4. Molecular dynamics simulation and dynophore calculations

Table S4. Assigned atom types and partial atomic charges of compound **1** using CHARMM General Force Field (CGenFF).

Name	Type	q	Name	Type	q
C1	CG2R57	-0,121	C18	CG2R61	-0,115
C2	CG2R57	0,277	H19	HGR61	0,155
N3	NG2R50	-0,638	H20	HGR61	0,250
C4	CG2R53	0,341	H21	HGR61	0,250
S5	SG2R50	0,015	H22	HGR61	0,115
C6	CG2R51	-0,239	H23	HGPAM1	0,376
H7	HGR52	0,210	C24	CG2R51	0,276
N8	NG311	-0,310	N25	NG2R50	-0,624
C9	CG2R61	-0,034	C26	CG2R53	0,280
C10	CG2R61	-0,115	S27	SG2R50	0,020
C11	CG2R61	-0,196	N28	NG321	-0,574
C12	CG2R61	-0,432	H29	HGPAM2	0,334
C13	CG302	0,803	H30	HGPAM2	0,334
F14	FGA3	-0,159	C31	CG331	-0,195
F15	FGA3	-0,159	H32	HGA3	0,090
F16	FGA3	-0,159	H33	HGA3	0,090
C17	CG2R61	-0,196	H34	HGA3	0,090

4.1 Measured time-dependant distances between selected protein atoms and Compound 1




Figure S4. Measured time-dependant distances between selected protein atoms and compound 1 during the MD simulation.

5. Results of the human topo II α and human topo II β decatenation assay

Table S5: Results of the decatenation assay catalysed by human topo II α for compounds **1** and **9** and positive control etoposide. Results are represented as % of decatenated kDNA.

Compound	% Decatenated Assay 1				% Decatenated Assay 2				% Decatenated Average			
	Concentration (μ M)				Concentration (μ M)				Concentration (μ M)			
	3.9	31.5	125	500	3.9	31.5	125	500	3.9	31.5	125	500
Etoposide	100	91	21.6	1.5	100	96.7	44	7.2	100	93.9	32.8	4.4
1	100	72.4	0	0	91	89.4	0	0	95.5	80.9	0	0
9	98.7	99.4	89.5	34	99.2	97.9	86.7	31.3	98.9	98.7	88.1	32.7

Table S6: Results of the decatenation assay catalysed by human topo II β for compounds **1** and **9** and positive control etoposide). Results are represented as % of decatenated kDNA.

Compound	% Decatenated Assay 1				% Decatenated Assay 2				% Decatenated Average			
	Concentration (μ M)				Concentration (μ M)				Concentration (μ M)			
	3.9	31.5	125	500	3.9	31.5	125	500	3.9	31.5	125	500
Etoposide	100.0	94.0	24.6	15.0	100.0	92.8	23.1	14.4	100.0	93.4	23.9	14.7
1	87.3	78.6	0	0	95.5	79.7	0	0	91.3	79.2	0	0
9	87.0	80.1	30.5	17.5	75.6	73.3	21.7	5.3	81.3	76.7	26.1	11.4




Figure S5: (A) Results of the second run of the decatenation assay of human topo II α for compounds **1**, **9** and etoposide. The assay was performed at 4 different concentrations (3.9, 31.5, 125 and 500 μ M) of compound **1** and **9** and reference compound etoposide. (B) Results of the second run of the decatenation assay of human topo II β for compounds **1**, **9** and

etoposide. The assay was performed at 4 different concentrations (3.9, 31.5, 125 and 500 μM) of compound **1**, **9** and reference compound etoposide.




Figure S6. Results of the first run of the human topo II α decatenation assay for compound **10** and etoposide. The assay was performed at 4 different concentrations (3.9, 31.5, 125 and 500 μM) of compound **10** and reference compound etoposide. Compound **10** inhibited 64% decatenation at concentration 500 μM and 26% at 125 μM . Experiment was performed in duplicates (second run is not shown).

6. Results of the human topo II α cleavage assay




Figure S7. Results of the second run of the topoisomerase II α cleavage assay. The assay was performed at 4 different concentrations (3.9, 31.5, 125 and 500 μ M) of compound **1** and **9** and reference compound etoposide. Linear band was measured as a % of the total DNA, with 100% representing the amount of DNA in track 1 (DNA alone).

Table S7. % of linear DNA, determined in the cleavage assay for compounds **1** and **9** and etoposide at four concentrations (500, 125, 31.5 and 3.9 μ M).

Compound	% Linear	% Linear	% Linear Average
DNA alone	0	0	0
DNA + topo II	55.5	4.08	4.81
DNA + topo II + DMSO	7.45	8.77	8.11
Etoposide 3.9 μ M	22.76	11.88	17.32
Etoposide 31.5 μ M	33.00	36.26	34.63
Etoposide 125 μ M	45.35	36.91	41.13
Etoposide 500 μ M	43.03	48.40	45.71
Compound 1 3.9 μ M	8.05	5.57	6.81
Compound 1 31.5 μ M	6.32	7.77	7.04
Compound 1 125 μ M	3.02	2.85	2.94
Compound 1 500 μ M	2.45	2.98	2.72
Compound 9 3.9 μ M	5.49	7.03	6.26
Compound 9 31.5 μ M	7.77	6.75	7.26
Compound 9 125 μ M	4.84	4.60	4.72
Compound 9 500 μ M	2.95	2.25	2.60

7. Results of the human topo II α ATPase activity




Figure S8. Results of the ATPase assay (second run) of compound **1**. It inhibited 85% of ATPase activity at 125 μ M. The reaction was performed at three concentrations (3.9, 31.5 and 125 μ M).




Figure S9. Results of the ATPase assay for etoposide (two runs). Results of the ATPase assay for the second run of compound **1**. The reaction was performed at four concentrations (3.9, 31.5, 125 and 500 μ M). Etoposide inhibited 70% (first run) or 63% (second run) of ATPase activity at 125 μ M.

Table S8. Results of the ATPase assay given as % activity which were calculated as follows: The spectrophotometer produces an output as change in OD340 with time. After 40 or 60 minutes the blank reading (no enzyme) was subtracted from the readings for each compound and divided by the positive reading (no inhibitor, 100% activity) minus the blank to give the percentage ATPase activity for each compound. There were solubility problems with compound **1** at 500 μM (erratic readings). 2 negative controls and 5 positive controls were run along with a 10 μM etoposide control.

	Rate ATPase activity ($\mu\text{mol}/\text{min}$)							
	Run 1				Run 2			
	No htII #1		0.26	No htII #2		0.21		
	htII only #1		3.35	htII only #2		3.12		
	htII only #3		3.33	htII only #4		3.14		
	htII only #5		3.19	+ novobiocin 10 μM		0.14		
	Average No htII		0.24	Average htII only		3.22		
	Percentage ATPase activity of compounds				Percentage ATPase activity of compounds			
Concentration (μM) Run 1				Concentration (μM) Run 2				
Compound	3.9	31.5	125	500	3.9	31.5	125	500
Etoposide	52.71	36.43	30.23	0	51.94	37.21	37.21	4.65
Compound 1	92.25	96.12	24.81	65.12	88.37	94.57	16.28	36.43

8. Human topoisomerase II ATPase assays at different concentration of the ATP – Competitive ATPase assay

The spectrophotometer produces an output as change in OD340 with time (data not shown). The data from the runs after the addition of the ATP were plotted after adjusting the starting OD340 to zero. Lines are fitted to these by linear regression and the rates (OD change/min) calculated. The rates for each ATP and inhibitor concentration were then calculated as μM ATP hydrolysed/min using an extinction coefficient of $6.22 \text{ M}^{-1} \text{ cm}^{-1}$ and a path length of 0.5 cm. The rates were then plotted against the ATP concentration and curves fitted to the data using the hyperbolic equation $y=(ax/(b+x))$ where $y = \text{rate}$, $x = [\text{ATP}]$, $a = V_{\text{max}}$ and $b=K_m$. Using the equation $y=y_0+(ax/(b+x))$ it was possible to solve it and obtain values.

Table S9: The table shows the rates ($\mu\text{M} /\text{min}$) at different compound and ATP concentrations after subtraction of the background rate and calculated K_m (mM ATP) and V_{max} (μM ATP/min) values. They were calculated from equation $y = (ax / (b+x))$ where $y = \text{rate}$, $x = [\text{ATP}]$, $a = V_{\text{max}}$.

Rates for controls without enzyme in the presence of 2 mM ATP ($\mu\text{mol}/\text{min}$)									
100 μM	75 μM	50 μM	31 μM	3.9 μM	0 μM				
1.125	0.515	0.354	0.354	0.257	0.386				
Rates ($\mu\text{mol}/\text{min}$) at different ATP concentrations (mM) after subtraction of background									
[Cp 1] μM	2	1	0.75	0.5	0.25	0.1	0.075	0.05	0.025
100	0.772	0.354	0.289	0.418	0.064	0.032	0.000	0.032	0.064
75	0.740	0.354	0.386	0.322	0.225	- 0.064	-0.096	0.032	0.096
50	1.222	0.772	0.707	0.450	0.193	0.032	0.129	0.096	0.000
31	1.286	1.061	0.868	0.707	0.450	0.161	0.096	- 0.032	-0.129
3.9	2.444	1.897	1.801	1.479	1.158	0.450	0.354	0.257	0.064
0	2.990	2.605	2.508	1.994	1.350	0.707	0.482	0.322	0.129
Calculated K_m (mM ATP) and V_{max} (μM ATP/min) values									
[Cp 1] μM	100	75	50	31	3.9	0			
K_m	6.14	3.35	2.5	0.88	0.49	0.41			
V_{max}	3.07	1.94	2.77	1.9	2.97	3.72			

9. Cytotoxicity on MCF-7 and HepG2 cell lines using MTS assay

Table S10. Determined cytotoxicity of the substituted 4,5'-bithiazoles represented by EC₅₀ values and value ranges on HepG2 and MCF-7 cancer cell lines (24h vs. 72h).

Compound	EC ₅₀ [μ M] MCF-7 (24h)	EC ₅₀ [μ M] MCF-7 (72h)	EC ₅₀ [μ M] HepG2 (24h)	EC ₅₀ [μ M] HepG2 (72h)
1	65.0 (58.1-70.9)	59.5 (58.1-59.3)	72.8 (64.2-86.1)	46.8 (47.1-49.3)
7	12.3 (10.4-14.9)	6.6 (4.6-7.6)	45.6 (32.8-53.7)	32.3 (29.7-37.2)
9	15.0 (11.2-16.2)	13.8 (9.7-15.9)	73.5 (59.6-80.8)	23.5 (17.1-32.1)
10	16.4 (14.6-17.0)	4.5 (3.4-5.9)	34.7 (31.5-38.9)	14.6 (12.7-19.5)
14	32.3 (28.2-34.3)	7.5 (5.2-6.7)	47.7 (31.7-60.4)	28.2 (20.5-29.9)
Etoposide	320.2 (226.9-358.9)	12.6 (10.1-15.9)	196.2 (169.4-201.5)	25.8 (15.1-35.3)

10. Investigation of the effect of 4,5'-bithiazoles on the cell cycle and cell proliferation




Figure S10. A) Representative histograms for non-labelled cells, vehicle control (0), compound **1** at 10 μM and 50 μM and etoposide at 50 μM for cell cycle analysis. (B) Percent of proliferative cells after 24h treatment to compound **1** at 50 μM and 10 μM determined with the Ki67 antibody (** $p < 0.01$ and *** $p < 0.001$).



Table S11. Results of cell cycle analysis for compound **1**. Experiments were performed in 3 independent measurements and SD values were calculated. Significant differences between the vehicle control (0) and treated cells (compound **1**) as well as PC (etoposide; 50 μM) were calculated using ANOVA (* $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$).

Compound	0	1 (10 μM)	1 (50 μM)	PC
G1	46.7 \pm 4.6	56.5 \pm 6.4	60.6 \pm 7.0*	33.1 \pm 2.4*
S	25.9 \pm 3.3	17.5 \pm 1.1***	11.8 \pm 4.5**	44.0 \pm 1.5***
G2	25.4 \pm 4.9	24.8 \pm 4.5	26.2 \pm 2.5	22.9 \pm 3.5
>G1, G2<	2 \pm 1.1	1.2 \pm 1.0	1.4 \pm 0.6	0


11. NMR, HR-MS, elemental analysis and HPLC purity of active compounds

- 1) The HR-MS analysis were performed at the Centre for Mass spectroscopy, Josef Stefan Institute, Ljubljana.
- 2) The ¹H-NMR spectra were supplied by vendors.
- 3) Elemental analysis was performed at the National Institute of Chemistry, Ljubljana using Perkin-Elmer C, H, N, S analyser.
- 4) HPLC purity measurements were performed at National Institute of Chemistry Slovenia




Compound 1



Compound 2



B0411948 DMSO-d6/CCL4=2:1 Dsh



Compound 3

Elemental Composition Report

Single Mass Analysis


Tolerance = 20.0 PPM / DBE: min = -1.5, max = 50.0
 Element prediction: Off
 Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions
 455 formula(e) evaluated with 9 results within limits (all results (up to 1000) for each mass)

Elements Used:


C: 0-100 H: 0-100 N: 0-20 O: 0-20 S: 2-2

Kaja Bergant
 7858097 50 (2.031) Cm (50-2.22)



Page 1

25-Oct-2018
 1: TOF MS ES+
 5.74e+005





Minimum:



Maximum:

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
331.0685	331.0687	-0.2	-0.6	10.5	494.1	0.1	C15 H15 N4 O S2
	331.0674	1.1	3.3	5.5	497.2	3.1	C14 H19 O5 S2
	331.0647	3.8	11.5	6.5	499.0	4.9	C10 H15 N6 O3 S2
	331.0634	5.1	15.4	1.5	500.2	6.2	C9 H19 N2 O7 S2
	331.0746	-6.1	-18.4	1.5	500.6	6.5	C8 H19 N4 O6 S2
	331.0620	6.5	19.6	7.5	501.1	7.0	C6 H11 N12 O S2
	331.0733	-4.8	-14.5	7.5	501.4	7.3	C5 H11 N14 S2
	331.0719	-3.4	-10.3	2.5	502.5	8.4	C4 H15 N10 O4 S2
	331.0692	-0.7	-2.1	3.5	504.8	10.8	H11 N16 O2 S2



B0411622 DMSO-D6/CCl4=2:1 Dah



Compound 4



Compound 5



Compound 6

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions


524 formula(e) evaluated with 6 results within limits (all results (up to 1000) for each mass)

Elements Used:


C: 0-100 H: 0-100 N: 0-20 O: 0-40 S: 2-2

Kaja Bergant

7859208 21 (0.868) Cm (20:21:4:8)




1: TOF MS ES-
8.48e+003



Minimum: -1.5
Maximum: 10.0 10.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
347.0272	347.0273	-0.1	-0.3	11.5	12.5	0.0	C14 H11 N4 O3 S2
	347.0259	1.3	3.7	6.5	16.2	3.8	C13 H15 O7 S2
	347.0246	2.6	7.5	12.5	18.1	5.6	C10 H7 N10 O S2
	347.0304	-3.2	-9.2	3.5	23.1	10.6	C3 H11 N10 O6 S2
	347.0291	-1.9	-5.5	-1.5	23.6	11.2	C2 H15 N6 O10 S2
	347.0291	-1.9	-5.5	9.5	24.5	12.1	H3 N20 S2

B9411623 DMSO-D6/CCL4=2:1 Dsh



Compound 7


Elemental Composition Report

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0
 Element prediction: Off
 Number of isotope peaks used for i-FIT = 3


Monoisotopic Mass, Even Electron Ions
 524 formula(e) evaluated with 5 results within limits (all results (up to 1000) for each mass)
 Elements Used:

C: 0-100 H: 0-100 N: 0-20 O: 0-20 S: 2-2
 Kaja Bergant
 5936031.26 (1.072) Cm (25.26-2.20)



Page 1


25-Oct-2018
 1: TOF MS ES+
 1.51e+006



Minimum:
 Maximum:

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
347.0630	347.0636	-0.6	-1.7	10.5	559.6	0.3	C15 H15 N4 O2 S2
	347.0623	0.7	2.0	5.5	560.7	1.5	C14 H19 O6 S2
	347.0610	2.0	5.8	11.5	563.4	4.1	C11 H11 N10 S2
	347.0596	3.4	9.8	6.5	564.4	5.1	C10 H15 N6 O4 S2
	347.0641	-1.1	-3.2	3.5	570.2	10.9	H11 N16 O3 S2

B07-94



h

Compound 8

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions



650 formula(e) evaluated with 8 results within limits (all results (up to 1000) for each mass)

Elements Used:

C: 0-100 H: 0-100 N: 0-20 O: 0-40 S: 2-2

Kaja Bergant



5934630 34 (1.385) Cm (33:35-6:15)



Minimum: -1.5
Maximum: 10.0 10.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
373.0420	373.0429	-0.9	-2.4	12.5	20.9	0.2	C16 H13 N4 O3 S2
	373.0416	0.4	1.1	7.5	22.7	1.9	C15 H17 O7 S2
	373.0402	1.8	4.8	13.5	24.4	3.7	C12 H9 N10 O S2
	373.0389	3.1	8.3	8.5	25.6	4.8	C11 H13 N6 O5 S2
	373.0448	-2.8	-7.5	-0.5	29.1	8.3	C4 H17 N6 O10 S2
	373.0447	-2.7	-7.2	10.5	29.6	8.9	C2 H5 N20 S2
	373.0434	-1.4	-3.8	5.5	30.3	9.6	C H9 N16 O4 S2
	373.0421	-0.1	-0.3	0.5	31.0	10.3	H13 N12 O8 S2

b14-69



Compound 9

Elemental Composition Report

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0
 Element prediction: Off
 Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions


710 formula(e) evaluated with 8 results within limits (all results (up to 1000) for each mass)

Elements Used:


C: 0-100 H: 0-100 N: 0-20 O: 0-20 S: 2-2

Kaja Bergant

5835030 40 (1.625) Cm (40-9:24)



Page 1




26-Oct-2018
 1: TOF MS ES+
 7.07e+005

Minimum:



Maximum:

Mass

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
388.0907	388.0902	0.5	1.3	11.5	398.5	0.6	C17 H18 N5 O2 S2
	388.0942	-3.5	-9.0	15.5	399.0	1.0	C22 H18 N3 S2
	388.0889	1.8	4.6	6.5	400.5	2.6	C16 H22 N O6 S2
	388.0875	3.2	8.2	12.5	403.4	5.5	C13 H14 N11 S2
	388.0934	-2.7	-7.0	3.5	407.3	9.3	C6 H18 N11 O5 S2
	388.0920	-1.3	-3.3	1.5	407.4	9.5	C5 H22 N7 O9 S2
	388.0907	0.0	0.0	4.5	409.7	11.8	C2 H14 N17 O3 S2
	388.0894	1.3	3.3	-0.5	410.4	12.5	C H18 N13 O7 S2



Compound 10



Compound 11

Elemental Composition Report


Page 1

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3



Monoisotopic Mass, Even Electron Ions

661 formula(e) evaluated with 9 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 0-100 H: 0-100 N: 0-20 O: 0-40 S: 2-2

Kaja Bergant

STK070262 37 (1.514) Cm (36:38-22:30)


1: TOF MS ES+
5.15e+004



Minimum:

Maximum: 10.0 10.0 -1.5

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
375.0581	375.0586	-0.5	-1.3	11.5	29.3	0.8	C16 H15 N4 O3 S2
	375.0572	0.9	2.4	6.5	29.7	1.2	C15 H19 O7 S2
	375.0559	2.2	5.9	12.5	31.0	2.5	C12 H11 N10 O S2
	375.0545	3.6	9.6	7.5	31.4	2.9	C11 H15 N6 O5 S2
	375.0617	-3.6	-9.6	3.5	31.7	3.2	C5 H15 N10 O6 S2
	375.0604	-2.3	-6.1	-1.5	31.9	3.4	C4 H19 N6 O10 S2
	375.0604	-2.3	-6.1	9.5	33.3	4.8	C2 H7 N20 S2
	375.0591	-1.0	-2.7	4.5	33.8	5.3	C H11 N16 O4 S2
	375.0577	0.4	1.1	-0.5	34.3	5.8	H15 N12 O8 S2



Compound 12

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions


515 formula(e) evaluated with 7 results within limits (all results (up to 1000) for each mass)

Elements Used:


C: 0-100 H: 0-100 N: 0-20 O: 0-40 S: 2-2

Kaja Bergant

5932282 43 (1.754) Cm (43:45-66:81)




1: TOF MS ES-
1.32e+004





Minimum: -1.5
Maximum: 10.0 10.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
345.0486	345.0520	-3.4	-9.9	15.5	24.8	0.3	C20 H13 N2 S2
	345.0480	0.6	1.7	11.5	26.6	2.0	C15 H13 N4 O2 S2
	345.0467	1.9	5.5	6.5	27.1	2.6	C14 H17 O6 S2
	345.0453	3.3	9.6	12.5	27.8	3.3	C11 H9 N10 S2
	345.0512	-2.6	-7.5	3.5	30.1	5.6	C4 H13 N10 O5 S2
	345.0498	-1.2	-3.5	-1.5	30.4	5.9	C3 H17 N6 O9 S2
	345.0485	0.1	0.3	4.5	31.2	6.7	H9 N16 O3 S2

60454404 DMSO-d6/CCL4 Dsh



ID 5932282 427.3404 C₁₅H₁₃N₄O₂S₂



Compound 13

Elemental Composition Report


Page 1

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3



Monoisotopic Mass, Even Electron Ions

724 formula(e) evaluated with 9 results within limits (all results (up to 1000) for each mass)


Elements Used:

C: 0-100 H: 0-100 N: 0-20 O: 0-40 S: 2-2

Kaja Bergant

5935989 33 (1.348) Cm (32:34-11:17)

1: TOF MS ES-
9.44e+003





Minimum:



Maximum: 10.0 10.0 -1.5

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
387.0589	387.0626	-3.7	-9.6	16.5	19.7	0.4	C22 H15 N2 O S2
	387.0586	0.3	0.8	12.5	20.9	1.6	C17 H15 N4 O3 S2
	387.0572	1.7	4.4	7.5	21.5	2.2	C16 H19 O7 S2
	387.0559	3.0	7.8	13.5	22.8	3.5	C13 H11 N10 O S2
	387.0617	-2.8	-7.2	4.5	25.6	6.3	C6 H15 N10 O6 S2
	387.0604	-1.5	-3.9	-0.5	25.9	6.6	C5 H19 N6 O10 S2
	387.0604	-1.5	-3.9	10.5	26.5	7.2	C3 H7 N20 S2
	387.0591	-0.2	-0.5	5.5	26.9	7.6	C2 H11 N16 O4 S2
	387.0577	1.2	3.1	0.5	27.3	8.0	C H15 N12 O8 S2

5935989G1



Compound 14



Etoposide

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions


2663 formula(e) evaluated with 29 results within limits (all results (up to 1000) for each mass)

Elements Used:


C: 0-100 H: 0-100 N: 0-20 O: 0-40

Kaja Bergant

Etoposide KI 31 (1.274) Cm (26:31-4:16)



1: TOF MS ES-
4.99e+003



Minimum: -1.5
Maximum: 10.0 10.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	i-FIT (Norm)	Formula
587.1750	587.1765	-1.5	-2.6	14.5	9.2	0.3	C29 H31 O13
	587.1738	1.2	2.0	15.5	11.4	2.5	C25 H27 N6 O11
	587.1751	-0.1	-0.2	20.5	11.6	2.7	C26 H23 N10 O7
	587.1778	-2.8	-4.8	19.5	11.8	2.9	C30 H27 N4 O9
	587.1724	2.6	4.4	10.5	12.6	3.7	C24 H31 N2 O15
	587.1765	-1.5	-2.6	25.5	12.7	3.8	C27 H19 N14 O3
	587.1738	1.2	2.0	26.5	14.1	5.3	C23 H15 N20 O
	587.1791	-4.1	-7.0	24.5	14.2	5.4	C31 H23 N8 O5
	587.1724	2.6	4.4	21.5	14.4	5.5	C22 H19 N16 O5
	587.1711	3.9	6.6	16.5	15.2	6.4	C21 H23 N12 O9
	587.1706	4.4	7.5	23.5	15.5	6.7	C36 H27 O8
	587.1719	3.1	5.3	28.5	15.6	6.8	C37 H23 N4 O4
	587.1733	1.7	2.9	33.5	15.7	6.9	C38 H19 N8
	587.1805	-5.5	-9.4	29.5	16.2	7.3	C32 H19 N12 O
	587.1760	-1.0	-1.7	32.5	16.2	7.3	C42 H23 N2 O2
	587.1783	-3.3	-5.6	1.5	16.4	7.5	C17 H35 N2 O20
	587.1756	-0.6	-1.0	2.5	16.5	7.6	C13 H31 N8 O18
	587.1698	5.2	8.9	11.5	16.5	7.6	C20 H27 N8 O13
	587.1770	-2.0	-3.4	7.5	16.5	7.6	C14 H27 N12 O14
	587.1692	5.8	9.9	29.5	16.6	7.8	C33 H19 N10 O2
	587.1797	-4.7	-8.0	6.5	16.7	7.8	C18 H31 N6 O16
	587.1783	-3.3	-5.6	12.5	16.9	8.0	C15 H23 N16 O10
	587.1796	-4.6	-7.8	17.5	17.3	8.4	C16 H19 N20 O6
	587.1743	0.7	1.2	8.5	18.5	9.6	C10 H23 N18 O12
	587.1729	2.1	3.6	3.5	19.1	10.2	C9 H27 N14 O16
	587.1800	-5.0	-8.5	36.5	19.4	10.5	C47 H23
	587.1716	3.4	5.8	-1.5	19.8	10.9	C8 H31 N10 O20
	587.1703	4.7	8.0	4.5	22.0	13.1	C5 H23 N20 O14
	587.1802	-5.2	-8.9	-0.5	22.1	13.2	C3 H27 N18 O17

Table S12. Elemental analysis data of active compounds **1**, **9** and **10**.

Compound	Molecular formula	Calculated				Found			
		C	H	N	S	C	H	N	S
1	C ₁₄ H ₁₁ N ₄ S ₂ F ₃	47.2	3.1	15.7	18.0	45.9	3.2	15.2	17.6
9	C ₁₇ H ₁₈ BrN ₅ O ₂ S ₂ X 2.5 H ₂ O	39.8	4.5	13.7	12.5	41.2	4.7	13.8	12.0
10	C ₁₆ H ₁₇ BrN ₄ O ₂ S ₂ X 4 H ₂ O	37.4	4.9	10.9	12.5	38.9	5.0	11.2	12.5

Table S13. HPLC purity data for active compounds **1**, **7**, **10** and **14**.

	Compound 1	Compound 7	Compound 10	Compound 14
Area (1%) (0.001 mg/mL)	66680342.00	149750383.00	59760385.00	281812961.00
Area TOTAL (100%) (1 mg/mL)	7084848214.00	4745097290.00	4193933896.00	6488929607.00
Area max (100%) (1 mg/mL)	6705645216.00	4663958201.00	4028846164.00	6101844241.00
Area (impurities 100%; TOTAL)	379202998.00	81139089.00	165087732.00	387085366.00
Purity [%]	94.31	99.46	97.24	98.63